You just read:

Athenex and Its Partner, Guangzhou Xiangxue Pharmaceutical, Announced Chinese FDA IND Approval to Begin Clinical Trials of KX-02 Tablet for Glioblastoma

News provided by

Athenex, Inc.

24 May, 2017, 12:43 ET